BRAF and melanoma: performed a positive selection screen from a genome‐scale CRISPR/Cas9 knockout library comprising 18 080 genes using a pooled lentiviral delivery of 64 751 unique guide sequences in melanoma cells, and identified a panel of genes including the previously validated NF1A and MED12, and novel hits NF2, CUL3, TADA2B, and TADA1, in which mutations conferred resistance to protein kinase BRAF inhibitor vemurafinib.[4]